NABCO ‘Celebrates Life’ and Honors Breast Cancer Survivors at Luncheon

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

NEW YORK-Wearing pink roses, more than 100 breast cancer survivors toasted each other at the National Alliance of Breast Cancer Organizations’ Celebrate Life luncheon, hosted by Academy Award winning actress Mira Sorvino.

NEW YORK—Wearing pink roses, more than 100 breast cancer survivors toasted each other at the National Alliance of Breast Cancer Organizations’ Celebrate Life luncheon, hosted by Academy Award winning actress Mira Sorvino.

At the luncheon, NABCO presented its Celebrate Life award to two women—Julia Child, culinary author, teacher, and television personality, who is a 30-year breast cancer survivor, and Catherine Viscardi Johnston, executive vice president of The Condé Nast Publications and a recent breast cancer survivor.

“Scientists and activists have changed the face of breast cancer in the time spanning the diagnoses of NABCO’s two honorees,” said Amy S. Langer, NABCO’s executive director and a 14-year breast cancer survivor. “Thirty years ago, breast cancer meant losing your breast and, too often, your life. Today, early detection and treatment advances mean that most women diagnosed are treated and go on with life—a life suddenly more precious, with much to celebrate.”

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content